LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

LLY

1,113.23

-0.21%↓

JNJ

228.14

-0.99%↓

ABBV

216.77

0%↓

UNH

377.97

-2.53%↓

MRK

119.15

-1.07%↓

Home・Listă Acțiuni・Puma Biotechnology Inc

Puma Biotechnology Inc

Deschisă

SectorSănătate

7.16 -2.32

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

7.12

Maxim

7.35

Indicatori cheie
By Trading Economics
Venit	-16M -3.8M
Vânzări	-31M 45M
P/E Medie Sector	14.75 50.102
EPS	-0.04
Marjă de profit	-8.375
Angajați	179
EBITDA	-28M -1.3M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-31.6% downside

Dividende
By Dow Jones
Următoarele câștiguri	6 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-23M 360M
Deschiderea anterioară	9.48
Închiderea anterioară	7.16

Sentimentul știrilor

By Acuity

100%

323 / 344 Clasament în Healthcare

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

28 mai 2026, 22:47 UTC

Câștiguri

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mai 2026, 20:45 UTC

Câștiguri

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mai 2026, 22:37 UTC

Market Talk

Achiziții, Fuziuni, Preluări

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mai 2026, 22:04 UTC

Achiziții, Fuziuni, Preluări

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mai 2026, 22:04 UTC

Achiziții, Fuziuni, Preluări

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mai 2026, 21:12 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mai 2026, 21:00 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mai 2026, 20:57 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:55 UTC

Câștiguri

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28 mai 2026, 20:48 UTC

Acțiuni populare

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mai 2026, 20:34 UTC

Câștiguri

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mai 2026, 20:31 UTC

Câștiguri

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mai 2026, 20:28 UTC

Câștiguri

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mai 2026, 20:26 UTC

Câștiguri

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mai 2026, 20:20 UTC

Câștiguri

Costco 3Q Membership Fees $1.37B

28 mai 2026, 20:20 UTC

Câștiguri

Costco 3Q Net Sales $69.15B

28 mai 2026, 20:19 UTC

Câștiguri

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mai 2026, 20:19 UTC

Câștiguri

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mai 2026, 20:17 UTC

Câștiguri

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mai 2026, 20:17 UTC

Câștiguri

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

-31.6% jos

Prognoză pe 12 luni

Medie 5 USD -31.6%

Maxim 5 USD

Minim 5 USD

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 1 analiști care au acordat evaluări ale acțiunilor Puma Biotechnology Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

323 / 344 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.